In NSCLC, the chemotherapy-resistance patients showed the activation of MTOR phosphorylation among KRAS-mutated variants (G12V and G13D), compared to the KRASWT patients [81]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.